SUV39H1 and lymphoma: When investigated in a trial-like fashion in the absence of an intact apoptotic response, we observed a dramatically shortened OS of the mouse cohort bearing senescence-incapable Suv39h1-deficient (hereafter referred to as Suv39h1−) lymphomas, thereby suggesting a critical role for TIS in the long-term outcome to therapy (Fig. 3b).